UK-based Mundipharma said Monday it has secured a partnership with Korea’s Samsung Bioepis to commercialize its first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).
Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain responsible for clinical development, regulatory registration and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO Raman Singh in a statement. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments.”